Onconova (NASDAQ: ONTX) was reduced by Zacks.com  from a “purchase” rating to a “hold” rating in a research note issued to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It focuses on discovering as well as creating tiny molecule drug candidates to treat cancer cells. The Business‘s items under various phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research analysts likewise lately discussed the firm. Noble Financial reissued a “purchase” ranking and also released a $11.00 cost objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating typical price of $2.90 as well as a two-hundred day moving average price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, topping experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also an adverse net margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, compared to the agreement quote of $0.06 million. During the very same quarter in the prior year, the company uploaded ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will publish -1.18 EPS for the existing year.

A variety of hedge funds have just recently bought and sold shares of ONTX. GSA Capital Allies LLP got a new position in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Monitoring LP purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a brand-new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional capitalists have 13.36% of the company’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition as well as growth of oncology therapeutics. It concentrates on finding and establishing little particle medication candidates to treat cancer cells. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more information about research offerings from Zacks Investment Research, see Zacks.com.

This instant news alert was produced by narrative scientific research modern technology as well as monetary data from Market in order to give visitors with the fastest as well as most exact reporting. This tale was examined by Market’s editorial group before publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS NOW?

Before you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market monitors Wall Street’s top-rated as well as ideal performing research analysts as well as the stocks they advise to their clients on a daily basis. Market has determined the 5 stocks that top analysts are quietly whispering to their clients to get currently before the broader market catches on … and Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” rating among analysts, top-rated experts think these five stocks are much better acquires.